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Summary
Malignant melanoma is rapidly increasing in the United States. Metastatic disease responds poorly to currently
available chemotherapy. Pyrazine diazohydroxide (PZDH) is a new agent inhibiting DNA synthesis that is active
in mouse tumor models and human xenografts and lacks cross resistance with multiple standard agents. In this
phase II trial, patients with no prior chemotherapy or immunotherapy for metastatic disease and performance status
(SWOG) of 0–1, were treated with pyrazine diazohydroxide at a dose of 100 mg/m2/day by IV bolus injection over
5–15 minutes for 5 consecutive days every 6 weeks. There were 23 eligible patients entered on this trial with 74%
having PS of 0 and 91% having visceral metastases. There were no confirmed anti-tumor responses. The overall
response rate is 0% (95% CI 0%–15%). Median overall survival is six months (95% CI 5-8 months). The most
common toxicities were hematologic and consisted of lymphopenia, thrombocytopenia, anemia, and leukopenia.
Fatigue, and nausea and vomiting were the next most common toxicities. Pyrazine diazohydroxide by this dose
and schedule has insufficient activity in the treatment of disseminated malignant melanoma to warrant further
investigation.
Introduction
There has been a steady increase in malignant melan-
oma in the United States over the last century with
now at least 47,000 new cases diagnosed per year [1].
Metastatic disease responds poorly to chemotherapy.
Dacarbazine is the standard agent with response rates
of 14% to 20% in multiple series and median response
durations of 4 to 6 months [1]. There is no defin-
ite evidence that dacarbazine produces any substantial
survival benefit and current controlled clinical trials
show no definite superiority for combination therapy
[1]. The biologic agents of interferon-α and inter-
leukin 2 each produce response rates around 15% and
are being tested in combinations [1]. With the lack of
overall survival benefit for patients with metastatic dis-
ease treated with known chemotherapy, patients with
metastatic melanoma are candidates for clinical trials
[1].
Pyrazine diazohydroxide (PZDH) was selected by
the National Cancer Institute for clinical development
because it was more chemically stable at physiologic
pH than its parent compound, pyridine -2- diazo-
hydroxide, and had shown significant antitumor activ-
ity in vivo against a variety of murine and human
tumors [2]. PZDH appeared to inhibit DNA syn-
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thesis by the intracellular formation of the pyrizinyl-
diazonium ion which then reacts with a nucleophile to
cause DNA adduct formation and single strand DNA
breaks [2]. The antitumor activity was first observed
in the intraperitoneal P388 leukemia prescreen. Max-
imum increased life span (ILS) values ranging from
87–261% in 17 experiments (median 158%) were ob-
tained following daily i.p. administration of PZDH in
the optimal dose range of 25–38 mg/kg for nine days
[2]. In additional intraperitoneally implanted mouse
tumor models with B16 melanoma and L1210 leuk-
emia, the administration of PZDH daily for 9 days
produced maximum increased life span values ran-
ging from 55%–69% and 36%–85% respectively, in
several experiments [2,3]. Intermittent treatment on
days 1, 5, 9, and 13 in the intraperitoneally implanted
M5076 sarcoma model produced similar results [2,3].
Of importance was the finding that activity against
the L1210 leukemia was significantly retained when
the tumor and drug injection sites were separated (s.c.
tumor and i.p. PZDH) [2].
PZDH at a 100 mg/kg dose administered intraperi-
toneally on days 1, 5, and 9, caused complete re-
gression of the human MX-1 mammary tumor placed
under the renal capsule of nude mice [3]. Using the
same dose and schedule, the life span of nude mice
bearing the intraperitoneally implanted human LOX
amelanotic melanoma was extended by 150% [3]. In
the i.p. LOX human melanoma model, four different
i.p. schedules, (day 5 only, q3h × 8 day 5, days 5, 9,
and 13, and qd 5–13), were equivalent with respect to
percent increased life span and cell kill [4]. The i.v.
route produced similar results [4]. P388 and L1210
leukemia cell lines resistant to melphalan were also
resistant to PZDH in vivo, but sensitivity to PZDH
was retained in P388 lines that were resistant to doxor-
ubicin, vincristine, cisplatin, cyclophosphamide, and
methotrexate [4]. By quantitative in vivo bioassay,
there appeared to be a 2 log greater cell kill in pulmon-
ary metastases then against the primary subcutaneous
LOX melanoma tumor in the same mouse [4]. In nude
mouse models where tumor was implanted subcu-
taneously in the flanks, PZDH was given at 100 mg/kg
i.p. on days 1, 8, and 15. The breast cancer model
MAXF 401 regressed completely 28 days after the
start of therapy, a partial remission was achieved in
the gastric cancer GXF 97, and a minor regression was
observed in the large-cell lung cancer [5].
Because PZDH shows an acid-catalyzed break-
down to the active agent, it is hypothesized that it
exhibits selective toxicity towards hypoxic solid tu-
mor cells. This was tested in vitro using A204 human
rhabdomyosarcoma cells to determine the drug con-
centration required to produce a 50% inhibition of
cell growth (IC 50) under different culture conditions.
With a one hour drug exposure at pH of 7.4, the IC 50
was 61 µg/ml while at pH of 6.0 it was 31 µg/ml [6].
Under hypoxic conditions in the presence of glucose,
stimulating production of lactic acid, the IC 50 at pH
7.4 was 22 µg/ml [6].
Preclinical toxicology and pharmacokinetic stud-
ies have been performed in CD2F1 mice, Fischer 344
rats, and beagle dogs. In mice, a single dose LD 10
is 166 mg/kg (498 mg/m2) and a five daily dose LD
10 is 60 mg/kg/day (180 mg/m2/day) [2]. The dose
limiting toxicity in both rats and dogs is myelosupres-
sion with decreases in leukocytes, and at higher doses,
red cells and platelets and bone marrow atrophy. Mild
GI toxicity and testicular atrophy also occurred [2].
In mice and dogs, pharmacokinetic analysis showed
a rapid, monophasic, dose-dependent elimination pat-
tern. Elimination half-lives ranged from 5.8 to 7.3
minutes and the rate of plasma drug clearance ranged
between 29.9 and 55 ml/min/kg [2]. Following an i.v.
bolus of 14C labeled pyrazine-2-diazohydroxide, 79%
of the radioactivity was excreted in the urine in 24
hours, 3% in the feces, 0.4% in the expired air, and
18% remained in the carcass with the highest levels of
radioactivity in the liver and kidney [7].
In humans, pharmacokinetic studies of 14 patients
treated at doses between 100 mg/m2 and 487 mg/m2
have confirmed that PZDH rapidly disappears from
plasma with an average elimination half life of 11.2
minutes [2]. There was a decrease in clearance and
in the volume of distribution as the dose was escal-
ated suggesting that there was a saturable component
to the elimination of PZDH [2]. Pharmacokinetic
analysis performed on 28 patients receiving between
18 mg/m2/d × 5 days and 100 mg/m2/d × 5 days of
PZDH revealed that at the lowest dose, drug could
only be detected for 30–90 minutes (assay detection
limit = 10 ng/ml) [8]. Compartmental modeling of
the four lowest dose levels (18–56 mg/m2/d × 5) was
consistent with a two-compartment model, while mod-
eling of the three higher doses (75–133 mg/m2/d × 5)
revealed a third phase to the decay curve. The AUC
increased progressively with dose and there was no
evidence of dose-dependent pharmacokinetics [8]. For
the 10 patients who received 100 mg/m2/d × 5, the
mean AUC was 105.4 µg min/ml and the rate of clear-
ance was 1.96 l/min. Peak plasma concentration varied
widely with a range from 4.1–80.2 µg/ml (mean 18.8
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and standard deviation 22.9 µg/ml) with a rapid drop
off [8]. Body surface area (BSA) was only moderately
correlated with clearance. BSA apparently correlated
with elimination but not with distribution [8].
There were 3 Phase I trials of PZDH in patients.
No objective responses occurred on these trials [2].
In trial 1, drug was administered once every 3 weeks
i.v. at doses ranging from 15 mg/m2 to 608 mg/m2.
The dose limiting toxicity was myelosuppression with
diarrhea, nausea and vomiting, anorexia, alopecia, and
decreased performance status also seen. Delayed my-
elosuppression was seen as the doses were escalated.
The recommended phase II dose was 487 mg/m2 i.v.
bolus once every 5 weeks [2]. In trial 2, drug was ad-
ministered by i.v. bolus once every 3 weeks at doses
from 50 mg/m2 to 350 mg/m2. Toxicities included
moderate to severe nausea and vomiting, anorexia, fa-
tigue, myelosuppression and headache. At the MTD
of 350 mg/m2 the dose limiting toxicity was life-
threatening hepatotoxicity seen twice, once after the
first course and once after the second course. There
was also a case of life-threatening pulmonary toxicity
possibly unrelated to the drug [2]. In trial 3, PZDH
was given i.v. at doses of ≤ 75 mg/m2 every 4 weeks
or at doses of > 75 mg/m2 every 6 weeks on a daily
× 5 schedule. Patients were treated at doses from
18–133 mg/m2. At the MTD of 133 mg/m2 Grade 3
and 4 toxicities included myelosuppression which was
dose limiting, elevated liver function tests, nausea and
vomiting, peripheral neuropathy, and fever [2]. One
death occurred on study. The recommended phase 2
dose was 100 mg/m2/d × 5 days every 6 weeks, the
dose used in this phase 2 trial.
Materials and methods
Patient population: All patients were required to have
a histologically proven diagnosis of malignant melan-
oma that was Stage IV and not surgically curable.
Patients had to have no evidence of brain metastases
by CT or MRI or if they had a history of brain meta-
stases, they had to be resected completely free of
disease followed by a course of radiation therapy.
They were required to have bi-dimensionally meas-
urable disease and a Southwestern Oncology Group
(SWOG) performance status of 0–1 (≥ 70 Karnofsky),
thus ambulatory and able to carry out light work. Pa-
tients may have received at most one prior biologic or
immunotherapy regimen given in an adjuvant fashion,
but no adjuvant chemotherapy and no prior chemother-
apy or immunotherapy for metastatic disease. Prior
surgery and/or radiation therapy was allowed provided
patients had recovered from all adverse effects of
prior treatments and, for prior radiation treatment,
had shown objective evidence of progression of dis-
ease. Patients had to have a pretreatment granulocyte
count of ≥ 1500 cells/µL a platelet count of ≥ the
institutional lower limit of normal and a hemoglobin
level ≥ 10/gm/dL serum creatinine and serum biliru-
bin within the institutional upper normal limits, and
a serum glutamic oxaloacetic transaminase level ≤
2.5 times the institutional upper limit of normal or
≤ 5 times the institutional upper limit of normal if
the liver was involved with tumor. Patients with other
serious illnesses, serious active infections, requiring
therapy with other investigational drugs, or known to
be human immunodeficiency virus antibody seroposit-
ive were not eligible. Pregnant or nursing women were
not eligible, nor were patients with a second malig-
nancy except for adequately treated basal or squamous
cell skin cancer or in situ cervical cancer, adequately
treated stage I or II cancer from which the patient
was currently disease free, or any other cancer for
which the patient has been disease free for at least five
years. Women or men of reproductive potential had
to agree to use an effective contraceptive method. No
type of concomitant therapy for the patient’s malignant
melanoma was allowed.
Pyrazine diazohydroxide: Pyrazine diazohydrox-
ide was supplied by the National Cancer Institute
(NCI) as a lyophilized powder in 500 mg. vials. When
reconstituted with 9.8 ml of Sterile Water for Injection
USP it formed a solution of 50 mg/ml. When diluted
to a concentration of 1 mg/ml for infusion it was stable
for 4 hours at room temperature.
Treatment plan: Pyrazine diazohydroxide was
given by IV bolus injection over 5–15 minutes at a
dose of 100 mg/m2/day for five consecutive days of
week one, followed by a five week rest period. Each
cycle was thus scheduled to be six weeks duration. It
was recommended that patients be aggressively pre-
treated with a potent antiemetic regimen (ondansetron
or granisetron plus dexamethasone) to prevent devel-
opment of serious nausea or vomiting. Toxicity was
evaluated using the Southwest Oncology Group Tox-
icity Criteria in place at the time of the study. Dose
reductions were required for grade 3 or 4 nausea or
vomiting that occurred despite aggressive antiemetic
treatment and could be done twice before removal
from treatment was required. Weekly CBC and plate-
lets counts were required after the first treatment and
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again in all subsequent cycles if grade 3 or 4 myel-
osuppression occurred. A grade 4 level of absolute
neutrophils (< 500 cells/µL) or platelets (< 25,000
cells/µL) required a 25% dose reduction of PZDH
in subsequent cycles. G-CSF could be used during
the dose reduction cycle and the dose could be es-
calated back to the original dose if the granulocyte
count remained ≥ 1000 cells/µL throughout the cycle
of G-CSF supported chemotherapy. Two 25% dose re-
ductions were allowed for grade 4 absolute neutrophil
count or thrombocytopenia before a patient would be
removed from treatment.
Definition of response: Standard SWOG response
criteria were used to define the antitumor effects that
were observed. A complete response required the dis-
appearance of all measurable and evaluable disease in
all disease sites including normalization of abnormal
disease-related laboratory values and disease-related
symptoms with no new lesions. A partial response re-
quired a ≥ 50% decrease in the sum of the products
of the perpendicular diameters of all measurable le-
sions, with no new lesions or progression of evaluable
disease with all measurable and evaluable disease and
sites assessed. Progressive disease was defined as (a)
a 50% increase or an increase of 10 cm2 (whichever
is smaller) in the sum of the products of measur-
able lesions over the smallest sum observed or clear
worsening of any evaluable disease, or (b) the appear-
ance of any new lesion or the reappearance of any
lesion that had disappeared, or (c) failure to return for
evaluation due to deteriorating condition (unless de-
terioration was clearly unrelated to the cancer). Stable
disease was disease that did not meet the criteria for
either a complete or partial response or progression.
Tumor assessment was requested at the end of every
two cycles. After first documentation of a complete
or partial response, a second assessment was required
after 4 weeks to confirm the response.
Statistical considerations: The primary goal of the
study was to evaluate the response rate in patients with
advanced melanoma. A two-stage design was used for
patient accrual. It was assumed that the regimen would
not be of interest if the true response rate were less
than 5%. It was also assumed that that a true response
rate of 20% or more would be of considerable interest.
Twenty eligible patients would be entered initially.
If necessary, the study would be temporarily closed
while response data matured. If zero responses were
observed, the study would be permanently closed and
the regimen concluded to be inactive. If one or more
responses were observed in the first 20 patients, an























additional 20 patients would be accrued. Five or more
responses out of 40 would be considered evidence that
the regimen warranted further study, provided other
factors, such as toxicity and survival also were favor-
able. This design had a significance level (probability
of declaring an agent with a 5% response probability to
warrant further study) of 5%, and a power (probability
of correctly declaring an agent with a 20% response
probability to warrant further study) of 92%.
Results
Patient population: Twenty four patients were entered
onto this study from 16 different institutions. One
patient was ineligible due to insufficient baseline doc-
umentation. The characteristics of the 23 eligible pa-
tients are listed in Table 1. Median age was 64 years
(range 33–83 years) and 74% were male. The ma-
jority, 74%, had a performance status of 0, while
26% had performance status of 1. Ninety one percent
of patients were M1b, thus having some site of vis-
ceral metastases. Seven patients, or 30%, had liver
involvement.
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Table 2. Response (N = 23)
Number Percent
Complete response 0 0%
Partial response 0 0%
Unconfirmed response 1 4%
Stable/No/Response 1 4%
Increasing disease 19 83%
Early death 1 4%
Assessment inadequate 1 4%
Total 23 100%
Response and survival: Response data are listed
in Table 2. All 23 eligible patients were evaluated for
response. One patient had inadequate response assess-
ment and one patient died prior to response assess-
ment. The patient that died had a stroke that was ap-
parently unrelated to either disease or treatment. Both
of these patients are assumed to be non-responders.
There were no confirmed responses. There was one
unconfirmed response in a patient with a lung nodule
and abdominal mass, but by the next evaluation there
were new lung, liver, spleen and abdominal lesions
indicating progression of disease. Thus, the overall re-
sponse rate is 0% with 95% confidence interval of 0%
to 15%. Twenty patients came off treatment because of
progression, one came off because of toxicity, and two
patients were off treatment due to death. The estimated
median number of courses received was 2 (range 1–
5). There were no major protocol deviations. Twenty
two of the 23 eligible patients have died. The median
overall survival is six months with a 95% confidence
interval of 5 months to 8 months.
Toxicity: All 23 eligible patients were evaluated
for toxicity (Table 3). The most common toxicit-
ies were hematologic and consisted of lymphopenia,
thrombocytopenia, anemia and leukopenia. Fatigue
and nausea/vomiting were also frequent. A decrease
in the number of lymphocytes is recorded as a tox-
icity in SWOG and so is reported here. Lymphopenia
occurred with high frequency and was often severe,
but its clinical relevance is uncertain. There was one
instance of grade 4 thrombocytopenia in a patient after
2 cycles of therapy. His platelets did not recover to
within normal range within the time frame allowed
by the study and he was removed from treatment. It
was necessary to combine several toxicities into broad
categories to make Table 3 manageable. The category
of Respiratory includes dyspnea, Neurologic includes
incoordination/ataxia, vision and headache, and Mis-
cellaneous includes insomnia, erythema, alopecia,
anxiety/depression, hyperglycemia, dehydration, and
GI, GU, Liver, and Dermatologic other than what
is specifically listed, and additional miscellaneous
toxicities.
Discussion: In this clinical trial, patients with ad-
vanced malignant melanoma were treated with the
promising new agent pyrazine diazohydroxide to as-
sess response and toxicity. PZDH had demonstrated
impressive in vitro activity in human xenograft tumor
models and lack of cross resistance to multiple com-
monly used agents, and theoretically, it might show
selective activity against hypoxic solid tumor cells.
Unfortunately, as is frequently seen, activity in in vitro
models failed to translate into this clinical area. A pub-
lished report by Vogelzang et al. [9], using the same
dose and schedule of PZDH as in this trial, indicated
that there were no antitumor responses in 15 renal
cell cancer patients and 14 colorectal cancer patients,
showing lack of significant antitumor activity in these
disease sites as well.
It is unlikely that this was due to an inferior sched-
ule of administration. In the mouse tumor models,
single day administration, 3 times a day administra-
tion, every 4 day administration, every 8 day adminis-
tration, and daily for 9 days, whether i.p. and i.v. were
equivalent with respect to increased life span and cell
kill [4]. In the human phase I trials in which drug was
administered once every 3 or 5 weeks, life threatening
hepatotoxicity and pulmonary toxicity were seen [2]
suggesting that the 5 day schedule might be better for
larger phase II trials.
In the mouse models, total dose of drug ad-
ministered on the different schedules varied from
128 mg/kg on the single day schedule to 513 mg/kg
on the daily times 9 day schedule [4]. Even the low-
est total dose of 128 mg/kg was larger than the dose
the average 70 kg. 5′8′′ (1.8 m2) person would re-
ceive at the dose and schedule used in this trial. At
100 mg/m2/day over 5 days the total dose administered
for a 1.8 m2 individual would be 900 mg or 12.9 mg/kg
assuming that they were 70 kg. Thus one reason that
responses were not seen may be because patients re-
ceived much smaller doses on a mg per kg basis then
was used in the mouse trials.
From [6], under optimal conditions in an in vitro
assay with a one hour continuous exposure, the lowest
concentration of drug producing a 50% inhibition of
tumor cell growth was 22 µg/ml. This gives an area
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Table 3. Toxicity (N = 23)
Any grade of toxicity Grade 3 Grade 4
Toxicity No. % No. No.
1. Lymphopenia 21 91 6 11
2. Thrombocytopenia 17 74 1 1
3. Anemia 15 65 3 0
4. Leukopenia/granulocytopenia 11 48 2 0
5. Malaise/fatigue/weakness 8 35 2 0
6. Pain 8 35 0 0
7. Nausea/vomiting/anorexia 7 30 1 0
8. Liver function abnormalities 6 26 2 0
9. Constipation 6 26 0 0
10. Renal 5 22 0 0
11. Fever/chills 5 22 0 0
12. Infection 4 17 4 0
13. Neurologic 3 13 2 0
14. Edema 3 13 0 0
15. Diarrhea 2 9 0 0
16. Stomatitis/gastritis 2 9 0 0
17. Rash/urticaria 2 9 0 0
18. Respiratory 1 4 1 0
19. Miscellaneous 10 43 1 0
under the curve of 1320 µg min/ml. From [8], Fig-
ure 2 is a representative time-concentration graph for
a patient treated with PZDH at the 100 mg/m2 dose
level. Estimating from this graph, the peak concen-
tration achieved in the blood is about 8.5 µg/ml and
rapidly falls off. For the first 60 minutes, the estimated
approximate area under the curve is 185 µg min/ml.
Going out to 500 minutes, the end of the graph, the
approximate total area under the curve is under 250 µg
min/ml. For 5 days of treatment, the estimated approx-
imate area under the curve would be less than 1250 µg
min/ml, total, of interrupted exposure. Thus, as in the
mouse data above, the in vitro data suggest that levels
of drug achieved in patients on this schedule is less
than the minimum required to produce meaningful cell
kill.
The toxicity that was seen in this trial was similar
in type and severity to that seen in the phase I trial re-
ported in reference 8. Our most common toxicity was
bone marrow, with decreases in all cell lines as shown
in table 3. There was one thrombocytopenia grade 3
(25.0–49.9 × 103/µL), and one grade 4 (< 25.0 ×
103/µL), and two leukopenia/granulocytopenias grade
3 (WBC 1.0–1.9 × 103/µL; granulocytes 0.5–0.9 ×
103/µL). Predominant toxicity was grade 1 or 2 (plate-
lets 50 × 103/µL – lower limit of normal; WBC
2.0–3.9 × 103/µL; granulocytes 1.0–1.9 × 103/µL).
In the phase I trial, at this dose level, median platelet
nadir was 87 × 103/µL (range 9–172 × 103/µL) cor-
responding to our grade 1, median WBC nadir was 2.5
× 103/µL (range 0.6–7.6 × 103/µL) corresponding to
our grade 2, and median absolute granulocyte count
was 1280/µL (range 50–5170/µL) again correspond-
ing to our grade 2. Though the numbers of patients
in the different trials are small, the types and sever-
ity of bone marrow toxicity that we saw, are similar
to the median and range of bone marrow toxicities
seen in the phase I trial and the two phase II trials in
renal and colorectal cancer [8,9]. In the phase I trial,
the variability in bone marrow toxicity was noted, but
there was insufficient data to determine if it was due to
pharmacokinetic variability or to other factors.
Though theoretically promising in the treatment of
cancer patients because of the encouraging preclinical
results, PZDH in the dose and schedule used here
demonstrated no benefit for the treatment of meta-
static melanoma. Although its dose might be increased
some, because of its significant toxicities, it is unlikely
that doses in humans equivalent to those producing
anti-tumor effects in mice or in vitro could be safely
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administered. In fact in the phase I trial, the dose of
133 mg/m2/day produced grade 4 neutropenia in 3 of
the 4 patients and grade 4 thrombocytopenia in 2 of the
4 patients in which it was tested. Although PZDH is
no longer in clinical development, testing of this com-
pound in pre-clinical models at lower doses, ones that
are achievable in patients, in combination with other
agents that have different toxicities, might be done to
evaluate for anti-tumor responses. If promising, there
might be a role for future trials of combination therapy
with PZDH in the clinic.
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